60P Sacituzumab govitecan (SG) + pembrolizumab (pembro) in first-line (1L) metastatic non-small cell lung cancer (mNSCLC): Efficacy results by histology from the EVOKE-02 study
Year: 2024
Type: article
Abstract: SG, a Trop-2–directed antibody-drug conjugate, has demonstrated activity and manageable safety in heavily pretreated patients with mNSCLC. EVOKE-02 (NCT05186974) is an open-label, multicohort phase II study evaluating SG + pembro ± a platinum agent in 1L mNSCLC. Here we report results by histology (squamous vs nonsquamous) in patients treated with SG + pembro in Cohorts A and B of EVOKE-02.
Source: ESMO Open
Authors: F. Cappuzzo, J. Patel, B.C. Cho, M. Cobo Dols, R.M. Reyes Cabanillas, D. Vicente Baz, J. Fuentes Pradera, J. Neal, E.B. Garon, S. Mekan, F. Safavi, N. Fernando, M. Chisamore, M. Reck
Institutions: Instituto Nazionale Tumori Regina Elena, Northwestern University, Yonsei University, Yonsei Cancer Hospital, Hospital Clínico Universitario Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga, Hospital Clínic de Barcelona, Hospital Universitario Virgen Macarena, Hospital Universitario de Valme, Stanford University, University of California, Los Angeles, Gilead Sciences (United States), Merck & Co., Inc., Rahway, NJ, USA (United States), German Center for Lung Research, LungenClinic Grosshansdorf
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,730
OpenAlex ID: W4393211416